← Leaderboards
Jill M Siegfried
University Of Pittsburgh At Pittsburgh
$10,296,579
Attributed
$10,584,477
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–19$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$38,461,263 · 13
By mechanism
P50$33,852,061 · 9
R01$3,709,186 · 1
R25$569,130 · 1
R21$325,886 · 1
R13$5,000 · 1
Top collaborators
- Yoji Shimizu5 shared
- Scott M. Dehm1 shared
- Carol Ann Lange1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Pamela A Moalli$8,505,235
- Naoki Yoshimura$12,168,895
- James M Roberts$7,171,578
- James L Funderburgh$10,362,544
- Michael S Sacks$16,621,157
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsBaseMalignant Neoplasm Of LungLung NeoplasmsResponseSignal TransductionTumorMalignant NeoplasmsEpidermal Growth Factor ReceptorCancer PatientMeetingsLigandsInhibitor/AntagonistEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorGrantLungClinical TrialsLaboratoriesResearch Project GrantsReceptor SignalingProgramsResearch PersonnelEnzymesReceptor Expression
Grant awards (64)
Cancer Research Education And Training Experience$102,465
R25 · FY2019 · CA
Cancer Research Education And Training Experience$118,769
R25 · FY2018 · CA
8th Great Lakes Nuclear Receptors Conference (GLNRC)$5,000
R13 · FY2018 · CA
Cancer Research Education And Training Experience$110,358
R25 · FY2017 · CA
Role of hormone pathways in chemoprevention for high risk smokers$169,792
R21 · FY2016 · CA · contact PI
Cancer Research Education And Training Experience$118,769
R25 · FY2016 · CA
Selective Targeting of Estrogen Pathways in Lung Cancer Using Biomarkers$286,876
P50 · FY2015 · CA · contact PI
Administrative Core$172,766
P50 · FY2015 · CA · contact PI
Role of hormone pathways in chemoprevention for high risk smokers$156,094
R21 · FY2015 · CA · contact PI
Cancer Research Education And Training Experience$118,769
R25 · FY2015 · CA
Selective Targeting of Estrogen Pathways in Lung Cancer Using Biomarkers$313,383
P50 · FY2014 · CA · contact PI
Administrative Core$179,899
P50 · FY2014 · CA · contact PI
Therapeutic Mechanisms of Co-Targeting of EGFR and Src Family Kinases$163,598
P50 · FY2014 · CA · contact PI
Selective Targeting of Estrogen Pathways in Lung Cancer Using Biomarkers$309,105
P50 · FY2013 · CA · contact PI
Therapeutic Mechanisms of Co-Targeting of EGFR and Src Family Kinases$269,429
P50 · FY2013 · CA · contact PI
Administrative Core$210,015
P50 · FY2013 · CA · contact PI
Targeting the HGF/c-Met Pathway in Lung Cancer$145,081
R01 · FY2013 · CA · contact PI
Targeting the HGF/c-Met Pathway in Lung Cancer$128,110
R01 · FY2013 · CA · contact PI
SPORE in Lung Cancer$2,300,000
P50 · FY2012 · CA · contact PI
Targeting the HGF/c-Met Pathway in Lung Cancer$290,629
R01 · FY2012 · CA · contact PI
Selective Targeting of Estrogen Pathways in Lung Cancer Using Biomarkers$263,971
P50 · FY2012 · CA · contact PI
Administrative Core$180,603
P50 · FY2012 · CA · contact PI
Therapeutic Mechanisms of Co-Targeting of EGFR and Src Family Kinases$179,759
P50 · FY2012 · CA · contact PI
SPORE in Lung Cancer$2,185,000
P50 · FY2011 · CA · contact PI
Targeting the HGF/c-Met Pathway in Lung Cancer$290,629
R01 · FY2011 · CA · contact PI
Therapeutic Mechanisms of Co-Targeting of EGFR and Src Family Kinases$184,984
P50 · FY2011 · CA · contact PI
SPORE in Lung Cancer$2,156,287
P50 · FY2010 · CA · contact PI
Targeting the HGF/c-Met Pathway in Lung Cancer$299,617
R01 · FY2010 · CA · contact PI
P1 - Intersection of Estrogen Receptor Signaling and EGF Receptor$274,725
P50 · FY2010 · CA · contact PI
Therapeutic Mechanisms of Co-Targeting of EGFR and Src Family Kinases$208,499
P50 · FY2010 · CA · contact PI
SPORE in Lung Cancer$2,156,287
P50 · FY2009 · CA · contact PI
SPORE in Lung Cancer$379,250
P50 · FY2009 · CA · contact PI
Targeting the HGF/c-Met Pathway in Lung Cancer$299,617
R01 · FY2009 · CA · contact PI
P1 - Intersection of Estrogen Receptor Signaling & EGF Receptor$274,668
P50 · FY2009 · CA · contact PI
SPORE in Lung Cancer$2,156,287
P50 · FY2008 · CA · contact PI
TARGETING EGFR AND GPCR SIGNALING IN SCCHN$541,164
P50 · FY2008 · CA · contact PI
Intersection of Estrogen Receptor Signaling and Epidermal Growth Factor Receptor$275,339
P50 · FY2008 · CA · contact PI
SPORE in Lung Cancer$5,120
P50 · FY2008 · CA · contact PI
SPORE in Lung Cancer$2,156,287
P50 · FY2007 · CA · contact PI
TARGETING EGFR AND GPCR SIGNALING IN SCCHN$503,783
P50 · FY2007 · CA · contact PI
Targeting the HGF/c-Met Pathway in Lung Cancer$285,130
R01 · FY2007 · CA · contact PI
INTERSECTION OF ESTROGEN RECEPTOR SIGNALING AND EPIDERMAL GROWTH FACTOR RECEPTOR$277,940
P50 · FY2007 · CA · contact PI
SPORE in Lung Cancer$25,953
P50 · FY2007 · CA · contact PI
SPORE in Lung Cancer$2,220,687
P50 · FY2006 · CA · contact PI
Targeting the HGF/c-Met Pathway in Lung Cancer$293,645
R01 · FY2006 · CA · contact PI
TARGETING EGFR AND GPCR SIGNALING IN SCCHN$205,379
P50 · FY2006 · CA · contact PI
INTERSECTION OF ESTROGEN RECEPTOR SIGNALING AND EPIDERMAL GROWTH FACTOR RECEPTOR$176,848
P50 · FY2006 · CA · contact PI
SPORE in Lung Cancer$125,000
P50 · FY2006 · CA · contact PI
ADMINISTRATIVE CORE$111,784
P50 · FY2006 · CA · contact PI
SPORE in Lung Cancer$2,255,788
P50 · FY2005 · CA
Targeting the HGF/c-Met Pathway in Lung Cancer$300,713
R01 · FY2005 · CA
TARGETING EGFR AND GPCR SIGNALING IN SCCHN$205,379
P50 · FY2005 · CA
SPORE in Lung Cancer$2,428,938
P50 · FY2004 · CA
Targeting the HGF/c-Met Pathway in Lung Cancer$300,713
R01 · FY2004 · CA
TARGETING EGFR AND GPCR SIGNALING IN SCCHN$205,379
P50 · FY2004 · CA
SPORE in Lung Cancer$2,516,090
P50 · FY2003 · CA
HGF AND THE PATHOLOGY OF LUNG CANCER$278,145
R01 · FY2003 · CA
SPORE in Lung Cancer$2,579,831
P50 · FY2002 · CA
HGF AND THE PATHOLOGY OF LUNG CANCER$270,656
R01 · FY2002 · CA
EXPRESSION OF GRPR AS A RISK FACTOR FOR LUNG CANCER$0
P50 · FY2002 · CA
SPORE in Lung Cancer$2,229,981
P50 · FY2001 · CA
HGF AND THE PATHOLOGY OF LUNG CANCER$270,599
R01 · FY2001 · CA
EXPRESSION OF GRPR AS A RISK FACTOR FOR LUNG CANCER$0
P50 · FY2001 · CA
HGF AND THE PATHOLOGY OF LUNG CANCER$255,902
R01 · FY2000 · CA